Literature DB >> 20944142

Down-regulation of P-glycoprotein is associated with resistance to cisplatin and VP-16 in human lung cancer cell lines.

Jiarui Wang1, Huiling Wang, Long Zhao, Sufang Fan, Zhonghai Yang, Fei Gao, Lixia Chen, Gary Guishan Xiao, Joseph Molnár, Qi Wang.   

Abstract

AIM: To investigate whether down-regulation of P-glycoprotein (P-gp) is correlated to resistance to cisplatin and VP-16 in four histopathological subtype cell lines of lung cancer (SK-MES-1, SPCA-1, NCI-H-460 and NCI-H-446).
MATERIALS AND METHODS: After pretreatment with or without verapamil, the P-gp expression was examined by means of RT-PCR and immunofluorescence. Cell survival on treatment with cisplatin and VP-16 was determined by MTT assay.
RESULTS: The expression of P-gp was clearly inhibited by verapamil in all four cell lines. Following pretreatment with verapamil, NCI-H-446 was more sensitive to cisplatin, while SPCA-1, NCI-H-460 and NCI-H-446 were more sensitive to VP-16 compared to the control.
CONCLUSION: Down-regulation of P-gp is associated with intrinsic resistance to cisplatin in the NCI-H-446 and to VP-16 in SPCA-1, NCI-H-460 and NCI-H-446 cell lines. These findings indicate that down-regulation of P-gp may be helpful for the reversion of drug resistance in some lung cancer cell line subtypes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20944142

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

Review 1.  Nanomedicine therapeutic approaches to overcome cancer drug resistance.

Authors:  Janet L Markman; Arthur Rekechenetskiy; Eggehard Holler; Julia Y Ljubimova
Journal:  Adv Drug Deliv Rev       Date:  2013-10-10       Impact factor: 15.470

2.  ECRG4 acts as a tumor suppressor and as a determinant of chemotherapy resistance in human nasopharyngeal carcinoma.

Authors:  Yanjie You; Wenjun Yang; Xin Qin; Fei Wang; Haijun Li; Canfeng Lin; Wenmei Li; Cunguo Gu; Yinpo Zhang; Yonggang Ran
Journal:  Cell Oncol (Dordr)       Date:  2015-02-24       Impact factor: 6.730

3.  Zoledronic acid reverses cisplatin resistance in nasopharyngeal carcinoma cells by activating the mitochondrial apoptotic pathway.

Authors:  Yanjie You; Haijun Li; Jiongyu Chen; Xin Qin; Yonggang Ran
Journal:  Oncol Lett       Date:  2017-01-18       Impact factor: 2.967

4.  Micro-RNA149 confers taxane resistance to malignant mesothelioma cells via regulation of P-glycoprotein expression.

Authors:  Rachael Kenworthy; Dale B Bosco; James T DeLigio; Diego A R Zorio
Journal:  Cancer Biol Ther       Date:  2018-01-15       Impact factor: 4.742

Review 5.  Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology.

Authors:  Xue Xue; Xing-Jie Liang
Journal:  Chin J Cancer       Date:  2012-01-09

6.  Reversal of Cisplatin resistance by epigallocatechin gallate is mediated by downregulation of axl and tyro 3 expression in human lung cancer cells.

Authors:  Kyung-Chan Kim; Chuhee Lee
Journal:  Korean J Physiol Pharmacol       Date:  2014-02-13       Impact factor: 2.016

Review 7.  Marine natural products with P-glycoprotein inhibitor properties.

Authors:  Dioxelis Lopez; Sergio Martinez-Luis
Journal:  Mar Drugs       Date:  2014-01-22       Impact factor: 5.118

8.  Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature.

Authors:  Martin P Barr; Steven G Gray; Andreas C Hoffmann; Ralf A Hilger; Juergen Thomale; John D O'Flaherty; Dean A Fennell; Derek Richard; John J O'Leary; Kenneth J O'Byrne
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240

9.  Characterization of human colorectal cancer MDR1/P-gp Fab antibody.

Authors:  Xuemei Zhang; Gary Guishan Xiao; Ying Gao
Journal:  ScientificWorldJournal       Date:  2013-11-07

10.  The influence of a caveolin-1 mutant on the function of P-glycoprotein.

Authors:  Chih-Yuan Lee; Ting-Yu Lai; Meng-Kun Tsai; Pu Ou-Yang; Ching-Yi Tsai; Shu-Wei Wu; Li-Chung Hsu; Jin-Shing Chen
Journal:  Sci Rep       Date:  2016-02-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.